HIV-Associated Kaposi's Sarcoma

@article{Hoffmann2017HIVAssociatedKS,
  title={HIV-Associated Kaposi's Sarcoma},
  author={Christian Hoffmann and Michael Sabranski and Stefan Esser},
  journal={Oncology Research and Treatment},
  year={2017},
  volume={40},
  pages={94 - 98}
}
Kaposi's sarcoma (KS) is still one of the most common malignancies in patients with human immunodeficiency virus (HIV) infection. Large randomized clinical trials have shown a protective effect of combination antiretroviral therapy (cART) against the development of KS, even in patients with a relatively preserved immune system. In patients with sufficient cART, KS has become a rarity. In most patients with HIV-associated KS who initiate cART, the KS lesions stabilize with decreasing HIV plasma… 

Tables from this paper

The course of Kaposi's sarcoma, a marker disease for the initial diagnosis of AIDS, under ongoing cART.

The course of KS in the first diagnosis of AIDS in a 36-year-old patient is described, whereby it was noted that new tumour lesions also developed focally in addition to individual progressive lesions, called Immune Reconstitution Inflammatory Syndrome.

Pulmonary Kaposi's Sarcoma - Initial Presentation of HIV Infection.

The need to strongly consider pulmonary KS as a possible cause for respiratory illness in any HIV-positive patient with cutaneous Kaposi’s sarcoma is emphasized in this case.

Molecular Mechanisms of Kaposi Sarcoma Development

Kaposi’s sarcoma-associated herpes virus (KSHV) is the underlying cause of this disease and impairs the immune response by various mechanisms such as the degradation of a variety of proteins involved in immune response or binding to cellular chemokines.

Necrotizing leg gangrene from invasive cutaneous Kaposi sarcoma, reversed by pegylated liposomal doxorubicin

A 64-year-old man with well-controlled HIV infection who developed necrotizing leg gangrene from invasive cutaneous Kaposi sarcoma responded very well to systemic chemotherapy, thereby avoiding limb amputation and illustrating that near complete and complete responses are possible with this agent, leading to potential limb salvage in necrotized gangrene.

Medical Care of Patient with HIV-Associated Kaposi’s Sarcoma: Case Report

The symptoms regressed, the risks that could develop in the patient were prevented, and the life quality of the patient increased in this shared case of a 37-year-old male patient diagnosed with HIV-associated Kaposi’s sarcoma.

Pulmonary Kaposi Sarcoma without Respiratory Symptoms and Skin Lesions in an HIV-Naïve Patient: A Case Report and Literature Review

A case of a pulmonary KS (pKS) in a human immunodeficiency virus (HIV) naïve patient, which was atypical due to a lack of cutaneous involvement and an absence of respiratory symptoms is reported, which led to the discovery of the HIV-seropositive status of the patient.

Multicentric Castleman’s disease in HIV patients: a single-center cohort diagnosed from 2008 to 2018

A retrospective, descriptive study on a cohort of patients with MCD, diagnosed and admitted to the infectious diseases or intensive care unit in the University Hospital Düsseldorf between 2008 and 2018, finding the most effective first-line therapy and retreatment option remains rituximab.

Kaposi’s sarcoma-associated herpesvirus protein ORF75 among HIV-1 patients in Kenya

Following the initial diagnosis of KS by histology, the ORF75 gene was fur-ther detected from both cases that had hallmark features of KS as well as among cases with KS-like fea-tures.

Kaposi’s Sarcoma Lesion Progression in BKV-Tat Transgenic Mice Is Increased by Inflammatory Cytokines and Blocked by Treatment with Anti-Tat Antibodies

Preliminary results are encouraging, indicating that anti-Tat Ab treatment or Tat-based vaccines may be effective to treat AIDS-KS patients or prevent the tumor in individuals at risk.

Clinicopathological Features and Mortality in Patients With Kaposi Sarcoma and HIV: A Retrospective Analysis of a Thirty-Year Study From a Peruvian Oncologic Center

Clinical and demographic characteristics of patients seen in the Instituto Nacional de Enfermedades Neoplasicas are compatible with the literature, but they report a higher rate of gastrointestinal involvement and the importance of HAART and its ability to reduce KS-related mortality is provided.

References

SHOWING 1-10 OF 42 REFERENCES

Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.

The added advantage of chemotherapy plus HAART compared to HAART alone; and the advantages of different chemotherapy regimens in HAART and HAART naive HIV infected adults with severe or progressive Kaposi's sarcoma are assessed.

Phase II study of bevacizumab in patients with HIV-associated Kaposi's sarcoma receiving antiretroviral therapy.

  • T. UldrickK. Wyvill R. Yarchoan
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
Bvacizumab is tolerated in patients with HIV-KS and has activity in a subset of patients, and overall response rate was 31% (95% CI, 11% to 58.7%).

Clinical activity of lenalidomide in visceral human immunodeficiency virus-related Kaposi sarcoma.

For the first time a patient with visceral Kaposi sarcoma successfully treated with lenalidomide is described, and good partial response without toxic effects has been reported in 3 patients with only skin involvement.

Differential impact of combination antiretroviral therapy in preventing Kaposi's sarcoma with and without visceral involvement.

The incidence of KS, and especially visceral KS, has fallen sharply since the advent of cART, likely due to immune restoration rather than to a specific effect on the tumoral process, as PI-containing and NNRTI-containing cART regimens had similar preventive efficacy.

Radiation therapy in the treatment of HIV-related Kaposi's sarcoma.

RT will be a mainstay of cure for this group of patients especially when of young age and the will to preserve the cosmetic appearance is a primary need.

Treatment of HIV-1-Associated Kaposi’s Sarcoma with Pegylated Liposomal Doxorubicin and HAART Simultaneously Induces Effective Tumor Remission and CD4+ T Cell Recovery

The simultaneous administration of HAART and liposomal doxorubicin is a safe and effective treatment approach for advanced Kaposi’s sarcoma and HAART-mediated recovery of relative CD4+ T cell counts does not seem to be impaired by concomitant treatment with liposomes.

Pilot study of oral valganciclovir therapy in patients with classic Kaposi sarcoma.

Oral valganciclovir was not active against KS in this setting, and other appropriately targeted anti-herpesviral strategies may prove to be more effective.

Prospective stage-stratified approach to AIDS-related Kaposi's sarcoma.

This stage-stratified approach to the management of Kaposi's sarcoma achieves high survival in patients with advanced KS and reduces exposure to chemotherapy in Patients with early-stage KS.

Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042.

  • H. KoonS. Krown A. Noy
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014
Imatinib is well tolerated and may be an alternative therapy for some patients with AIDS-KS and Pharmacokinetic interactions with antiretroviral drugs did not correlate with toxicity.

The changing pattern of Kaposi sarcoma in patients with HIV, 1994–2003

The goals of the current study were to assess the change in the incidence of Kaposi sarcoma among European patients with HIV since the introduction of HAART and to identify the factors associated with the development of KS among patients receiving HAART.